FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2045178802> ?p ?o ?g. }

• W2045178802 endingPage "164" @default.
• W2045178802 startingPage "156" @default.
• W2045178802 abstract "ObjectiveStudies have indicated that ginsenoside Rb1 and ghrelin could both prevent homocysteine (Hcy)-induced endothelial dysfunction through the endothelial nitric oxide synthase (eNOS)/nitric oxide (NO) mechanism. This study investigated whether endogenous ghrelin mediates the endothelial protection of ginsenosidee Rb1 through in vitro and in vivo experiments.MethodsRats were randomized into a control group, a hyperhomocysteine (HHcy) model group with a high methionine diet, a ginsenosides (GS) group, and HHcy plus GS group. Plasma ghrelin was detected by enzyme-linked immunosorbent assay. Aortic rings for control and HHcy groups were treated with ghrelin or not. Endothelium-dependent vasodilatation function was evaluated by the aortic ring assay, and the structural changes were visualized by hematoxylin and eosin staining. Human umbilical vein endothelial cells (HUVECs) were cultured, and the experimental conditions were optimized according to NO production. After treatment, the NO, ghrelin, and von Willebrand factor (vWF) levels in the media were detected and analyzed with linear regression. Ghrelin and eNOS expression were observed by cell immunohistochemical staining. Ghrelin receptor antagonist was used to detect the mechanism of ginsenoside Rb1 on NO production, which was reflected by diacetylated 4,5-diaminofluorescein-2 diacetate fluorescence.ResultsIn vivo experiments demonstrated that plasma ghrelin levels in the HHcy group were significantly elevated vs controls (P < .05) and were significantly increased in the HHcy plus GS group (P < .01). Compared with control, endothelium-dependent vasodilatation function was greatly reduced in the HHcy group (P < .01), which was significantly increased in HHcy plus ghrelin group compared with HHcy group (P < .01). The arterial walls of HHcy group exhibited characteristic pathologic changes, which were repaired in HHcy plus ghrelin group. In vivo, compared with Hcy (200 μM) group, HUVECs pretreated with ginsenoside Rb1 (10 μM) for 30 minutes showed significant increases in NO and ghrelin levels and evident reduction in vWF levels. Linear regression analysis demonstrated that ghrelin levels were significantly positively correlated with NO levels and significantly negatively correlated with vWF levels. The addition of Rb1 to Hcy also greatly reversed Hcy-induced downregulation of ghrelin and eNOS expression. Ghrelin inhibition significantly abolished the upregulation of NO levels induced by Rb1.ConclusionGhrelin can prevent Hcy-induced vascular endothelial dysfunction and structural damage. The compensatory elevation of plasma ghrelin levels in an Hcy-induced endothelial injury model may be a protective response. Ginsenoside Rb1 can significantly stimulate the ghrelin endocrine to inhibit endothelial injury. Ginsenoside also upregulates the NO signaling pathway reduced by Hcy through the ghrelin molecular mechanism. Studies have indicated that ginsenoside Rb1 and ghrelin could both prevent homocysteine (Hcy)-induced endothelial dysfunction through the endothelial nitric oxide synthase (eNOS)/nitric oxide (NO) mechanism. This study investigated whether endogenous ghrelin mediates the endothelial protection of ginsenosidee Rb1 through in vitro and in vivo experiments. Rats were randomized into a control group, a hyperhomocysteine (HHcy) model group with a high methionine diet, a ginsenosides (GS) group, and HHcy plus GS group. Plasma ghrelin was detected by enzyme-linked immunosorbent assay. Aortic rings for control and HHcy groups were treated with ghrelin or not. Endothelium-dependent vasodilatation function was evaluated by the aortic ring assay, and the structural changes were visualized by hematoxylin and eosin staining. Human umbilical vein endothelial cells (HUVECs) were cultured, and the experimental conditions were optimized according to NO production. After treatment, the NO, ghrelin, and von Willebrand factor (vWF) levels in the media were detected and analyzed with linear regression. Ghrelin and eNOS expression were observed by cell immunohistochemical staining. Ghrelin receptor antagonist was used to detect the mechanism of ginsenoside Rb1 on NO production, which was reflected by diacetylated 4,5-diaminofluorescein-2 diacetate fluorescence. In vivo experiments demonstrated that plasma ghrelin levels in the HHcy group were significantly elevated vs controls (P < .05) and were significantly increased in the HHcy plus GS group (P < .01). Compared with control, endothelium-dependent vasodilatation function was greatly reduced in the HHcy group (P < .01), which was significantly increased in HHcy plus ghrelin group compared with HHcy group (P < .01). The arterial walls of HHcy group exhibited characteristic pathologic changes, which were repaired in HHcy plus ghrelin group. In vivo, compared with Hcy (200 μM) group, HUVECs pretreated with ginsenoside Rb1 (10 μM) for 30 minutes showed significant increases in NO and ghrelin levels and evident reduction in vWF levels. Linear regression analysis demonstrated that ghrelin levels were significantly positively correlated with NO levels and significantly negatively correlated with vWF levels. The addition of Rb1 to Hcy also greatly reversed Hcy-induced downregulation of ghrelin and eNOS expression. Ghrelin inhibition significantly abolished the upregulation of NO levels induced by Rb1. Ghrelin can prevent Hcy-induced vascular endothelial dysfunction and structural damage. The compensatory elevation of plasma ghrelin levels in an Hcy-induced endothelial injury model may be a protective response. Ginsenoside Rb1 can significantly stimulate the ghrelin endocrine to inhibit endothelial injury. Ginsenoside also upregulates the NO signaling pathway reduced by Hcy through the ghrelin molecular mechanism." @default.
• W2045178802 created "2016-06-24" @default.
• W2045178802 creator A5001787712 @default.
• W2045178802 creator A5003736471 @default.
• W2045178802 creator A5037817685 @default.
• W2045178802 creator A5079940252 @default.
• W2045178802 date "2011-01-01" @default.
• W2045178802 modified "2023-09-25" @default.
• W2045178802 title "The effects of ginsenoside Rb1 on endothelial damage and ghrelin expression induced by hyperhomocysteine" @default.
• W2045178802 cites W1964962284 @default.
• W2045178802 cites W1967715179 @default.
• W2045178802 cites W1969119140 @default.
• W2045178802 cites W1971875923 @default.
• W2045178802 cites W1973807604 @default.
• W2045178802 cites W1979588112 @default.
• W2045178802 cites W1979929836 @default.
• W2045178802 cites W1990946950 @default.
• W2045178802 cites W2007221249 @default.
• W2045178802 cites W2007608981 @default.
• W2045178802 cites W2010761547 @default.
• W2045178802 cites W2024075397 @default.
• W2045178802 cites W2025423183 @default.
• W2045178802 cites W2026143432 @default.
• W2045178802 cites W2036881655 @default.
• W2045178802 cites W2040235262 @default.
• W2045178802 cites W2055075631 @default.
• W2045178802 cites W2063454939 @default.
• W2045178802 cites W2070804621 @default.
• W2045178802 cites W2074810985 @default.
• W2045178802 cites W2084962003 @default.
• W2045178802 cites W2101689888 @default.
• W2045178802 cites W2102790142 @default.
• W2045178802 cites W2117095264 @default.
• W2045178802 cites W2133124714 @default.
• W2045178802 cites W2153524297 @default.
• W2045178802 cites W2162250897 @default.
• W2045178802 cites W2163865122 @default.
• W2045178802 doi "https://doi.org/10.1016/j.jvs.2010.06.170" @default.
• W2045178802 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20801605" @default.
• W2045178802 hasPublicationYear "2011" @default.
• W2045178802 type Work @default.
• W2045178802 sameAs 2045178802 @default.
• W2045178802 citedByCount "18" @default.
• W2045178802 countsByYear W20451788022012 @default.
• W2045178802 countsByYear W20451788022013 @default.
• W2045178802 countsByYear W20451788022014 @default.
• W2045178802 countsByYear W20451788022015 @default.
• W2045178802 countsByYear W20451788022016 @default.
• W2045178802 countsByYear W20451788022017 @default.
• W2045178802 countsByYear W20451788022018 @default.
• W2045178802 countsByYear W20451788022019 @default.
• W2045178802 countsByYear W20451788022020 @default.
• W2045178802 countsByYear W20451788022022 @default.
• W2045178802 crossrefType "journal-article" @default.
• W2045178802 hasAuthorship W2045178802A5001787712 @default.
• W2045178802 hasAuthorship W2045178802A5003736471 @default.
• W2045178802 hasAuthorship W2045178802A5037817685 @default.
• W2045178802 hasAuthorship W2045178802A5079940252 @default.
• W2045178802 hasBestOaLocation W20451788021 @default.
• W2045178802 hasConcept C120770815 @default.
• W2045178802 hasConcept C126322002 @default.
• W2045178802 hasConcept C134018914 @default.
• W2045178802 hasConcept C170493617 @default.
• W2045178802 hasConcept C202751555 @default.
• W2045178802 hasConcept C2776992346 @default.
• W2045178802 hasConcept C2777411675 @default.
• W2045178802 hasConcept C2777622882 @default.
• W2045178802 hasConcept C2778326061 @default.
• W2045178802 hasConcept C2779357093 @default.
• W2045178802 hasConcept C2779394231 @default.
• W2045178802 hasConcept C2780972559 @default.
• W2045178802 hasConcept C519581460 @default.
• W2045178802 hasConcept C55493867 @default.
• W2045178802 hasConcept C71924100 @default.
• W2045178802 hasConcept C86803240 @default.
• W2045178802 hasConcept C89560881 @default.
• W2045178802 hasConceptScore W2045178802C120770815 @default.
• W2045178802 hasConceptScore W2045178802C126322002 @default.
• W2045178802 hasConceptScore W2045178802C134018914 @default.
• W2045178802 hasConceptScore W2045178802C170493617 @default.
• W2045178802 hasConceptScore W2045178802C202751555 @default.
• W2045178802 hasConceptScore W2045178802C2776992346 @default.
• W2045178802 hasConceptScore W2045178802C2777411675 @default.
• W2045178802 hasConceptScore W2045178802C2777622882 @default.
• W2045178802 hasConceptScore W2045178802C2778326061 @default.
• W2045178802 hasConceptScore W2045178802C2779357093 @default.
• W2045178802 hasConceptScore W2045178802C2779394231 @default.
• W2045178802 hasConceptScore W2045178802C2780972559 @default.
• W2045178802 hasConceptScore W2045178802C519581460 @default.
• W2045178802 hasConceptScore W2045178802C55493867 @default.
• W2045178802 hasConceptScore W2045178802C71924100 @default.
• W2045178802 hasConceptScore W2045178802C86803240 @default.
• W2045178802 hasConceptScore W2045178802C89560881 @default.
• W2045178802 hasIssue "1" @default.
• W2045178802 hasLocation W20451788021 @default.
• W2045178802 hasLocation W20451788022 @default.
• W2045178802 hasOpenAccess W2045178802 @default.
• W2045178802 hasPrimaryLocation W20451788021 @default.

• next